60 DEGREES PHARMACEUTICALS, INC. (SXTP)
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
60 Degrees Pharmaceuticals, Inc.
- tafenoquine (ARAKODA)READOUTCash runway at this date: -6mo
- tafenoquineREADOUTCash runway at this date: -6mo
- Cash runway at this date: -17mo
Trials need funding. See this company's dilution risk and cash position.
- Oct 28, 2026castanospermine
- Phase 2Completed
Long-Term Safety Study of Tafenoquine
Tafenoquine
Healthy Volunteers
NCT03320174Enrollment600StartOct 2017Primary CompletionJul 2021CompletionJul 2021 - Phase 2Completed
Tafenoquine in Patients With Mild to Moderate COVID-19
Tafenoquine Oral Tablet, Placebo
COVID 19 Disease
NCT04533347Enrollment86StartFeb 2021Primary CompletionJun 2022CompletionJun 2022 - Phase 2Recruiting
Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis
Tafenoquine
Babesiosis
NCT06207370Enrollment33StartJun 2024Primary CompletionMar 2027est.READOUTCompletionJul 2027est. - Phase 2Recruiting
B-FREE Chronic Babesiosis Study
Tafenoquine 100mg
Chronic Babesiosis
NCT06656351Enrollment40StartNov 2025Primary CompletionFeb 2027est.CompletionSep 2027est. - Expanded accessAvailable
Expanded Use in Persistent (B. Microti) Babesiosis
Tafenoquine
Persistent Babesiosis
NCT06478641Enrollment-Start-Primary Completion-READOUT • p=0.019Completion-
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 2 | Completed | Tafenoquine | NCT03320174 |
| Phase 2 | Completed | Tafenoquine Oral Tablet, Placebo | NCT04533347 |
| Phase 2 | Recruiting | Tafenoquine | NCT06207370 |
| Phase 2 | Recruiting | Tafenoquine 100mg | NCT06656351 |
| Expanded access | Available | Tafenoquine | NCT06478641 |